Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Acute myeloid leukemia (AML) is the most common form of aggressive hematologic malignancy affecting adults. AML is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is a relatively rare disease, however its incidence increases with age, thus it is expected to become more prominent as the global population ages.

Read more

Syngeneic models were developed over 50 years ago as early in vivo models for oncology drug development, consisting of allograft of murine tumor cells in hosts with a fully functional immune system. After an initial phase of great popularity they drifted out of the drug discovery landscape with the shift towards therapies directed against human targets, when they were replaced by models expressing human targets, such as genetically engineered mouse models (GEMM) or PDX.

Read more

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in developed countries, occurring when fat is deposited in the liver, independently from excessive alcohol use. NAFLD affects approximately 20% of the United States population and 25-30% of people in the UK, according to a recent study using the National Health and Nutrition Examination Survey (NHANES). There is no current licensed treatment for NAFLD, however new research showed that a drug, currently in use for the treatment of Type II diabetes, can be effective in clearing liver fat in some patients.

Read more